Global Alliance for Genomics and Health

Cirrus Data Reaches Milestone of Over an Exabyte of Block Data Migrated

Retrieved on: 
Wednesday, February 15, 2023
Cloud, Organization, Acceleration, Azure, Amazon Web Services, Executive, AWS, Marketing, Customer support, Microsoft, Microsoft Azure, Amazon, Oracle Cloud, Growth, Global Alliance for Genomics and Health, Cryptocurrency, Management

SYOSSET, N.Y., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cirrus Data Solutions (“CDS”), the market leader in block data mobility technology and services, today announced that organizations globally have trusted Cirrus Data to migrate over an exabyte of mission-critical block data.

Key Points: 
  • SYOSSET, N.Y., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cirrus Data Solutions (“CDS”), the market leader in block data mobility technology and services, today announced that organizations globally have trusted Cirrus Data to migrate over an exabyte of mission-critical block data.
  • Cirrus Data is honored that these businesses entrust our solutions to migrate their mission-critical block data.
  • Cirrus Data is proud to have migrated over an exabyte of block data to new storage platforms.
  • Mr. Donald joined Cirrus Data in 2019, helping expand the market for Cirrus Data in Asia Pacific, South Africa, and India.

Kyndryl, Microsoft and Dell Technologies Unveil Solution to Advance Customers’ Cloud Transformation

Retrieved on: 
Friday, October 14, 2022
Data Management, Apps, Applications, Technology, Mobile, Wireless, Software, Networks, Cloud, IOT, Telecommunication, General manager, NYSE, Microsoft, Partnership, Solution, KD, Global Alliance for Genomics and Health, Company, Glass, HCI, Partner development, Microsoft Power Platform, ROBO, Maintenance, Dell PowerEdge, Microsoft Azure, Dell Technologies, Azure, Dell, Integral Systems, Video game console, IBM Global Services

Kyndryl (NYSE: KD), the worlds largest IT infrastructure services provider, Microsoft Corporation and Dell Technologies today introduced an integrated hybrid cloud solution designed to help customers in data center, mainframe and remote environments accelerate cloud transformation projects by combining the strengths of Microsoft Azure, Kyndryl managed services and Dell Technologies infrastructure.

Key Points: 
  • Kyndryl (NYSE: KD), the worlds largest IT infrastructure services provider, Microsoft Corporation and Dell Technologies today introduced an integrated hybrid cloud solution designed to help customers in data center, mainframe and remote environments accelerate cloud transformation projects by combining the strengths of Microsoft Azure, Kyndryl managed services and Dell Technologies infrastructure.
  • The new Kyndryl Distributed Cloud for Microsoft Azure Stack hyperconverged infrastructure (HCI) with Azure Arc consists of Dell Integrated System for Azure Stack HCI , based on Dell PowerEdge servers and Microsoft Azure Stack HCI software.
  • We are thrilled that this collaboration with Kyndryl and Dell Technologies is a best-in-class distributed cloud solution, powered by Azure Stack HCI and Azure Arc, that will help customers realize the benefits of cloud transformation.
  • Dell Technologies, Microsoft and Kyndryl are well positioned to deliver hybrid cloud solutions that help customers modernize their data centers.

RARE-X Releases New Report that Uncovers Large Number of Previously Uncounted Rare Diseases

Retrieved on: 
Tuesday, June 7, 2022
Research, Public Policy, Government, Philanthropy, Biotechnology, White House, Federal Government, General Health, Pharmaceutical, Health, Foundation, Science, Acceleration, Congress, DrugBank, Lists of diseases, Food, CEO, Alexion Pharmaceuticals, Disease, Awareness, OMIM, Organization, Knowledge, Degenerative disease, Patient, Risk, Global Alliance for Genomics and Health, OOD, Radar, The Monarch Initiative, GA4GH, Genomics, Medical device, Pharmaceutical industry, Health

Ensuring that the true magnitude of rare diseases is understood is critical, said Charlene Son Rigby, CEO of RARE-X.

Key Points: 
  • Ensuring that the true magnitude of rare diseases is understood is critical, said Charlene Son Rigby, CEO of RARE-X.
  • If patient communities, researchers, drug developers, and policymakers are to address rare diseases, its essential to understand the magnitude of the problem.
  • The study authors developed a reproducible methodology to identify the accurate number of rare diseases.
  • The analysis showed that there are as many as 10,867 rare diseases, including genetic and non-genetic diseases.

Hammerspace Joins Global Alliance for Genomics and Health

Retrieved on: 
Tuesday, May 3, 2022
Global Alliance for Genomics and Health, Information technology, Data management, Medicine, HPC, Genomics, Organization, Microscopy, Precision medicine, GA4GH, Global Alliance, CEO, Technology, Research, SAN, Framework, Medical device, Cryptocurrency, Hammerspace, Health

BOSTON and SAN MATEO, Calif., May 3, 2022 /PRNewswire-PRWeb/ -- Hammerspace, the pioneer of the Global Data Environment, today announced that it has joined the Global Alliance for Genomics and Health. Hammerspace will partner with more than 600 of the world's leading healthcare, research, patient advocacy, life science and information technology organizations to create the frameworks and standards for sharing genomic and health-related data.

Key Points: 
  • Hammerspace has joined the Global Alliance for Genomics and Health, partnering with more than 600 of the world's leading healthcare, research, patient advocacy, life science and information technology organizations to aid the sharing of genomic and health-related data.
  • BOSTON and SAN MATEO, Calif., May 3, 2022 /PRNewswire-PRWeb/ -- Hammerspace , the pioneer of the Global Data Environment, today announced that it has joined the Global Alliance for Genomics and Health .
  • Hammerspace is committed to working together with member organizations to help bring the vision of the Global Alliance for Genomics and Health to fruition.
  • The Global Alliance for Genomics and Health (GA4GH) is an international, nonprofit alliance formed in 2013 to accelerate the potential of research and medicine to advance human health.

Acceldata Adds Three Data Industry Veterans to Leadership Team

Retrieved on: 
Tuesday, December 14, 2021
Cloud, Organization, Software as a service, Product management, MLOps, Global Alliance for Genomics and Health, Business, SAN, PhonePe, Google, Pratt & Whitney, Entrepreneurship, Yahoo!, AI, Partnership, DBS, Heel, CEO, General manager, Engineering, Insight Partners, VP, Efficiency, Multimedia, Cisco Webex, Data, APM, Technology, Box, View, Management, Online shopping, Whatfix, Oracle, Hortonworks, Pubmatic, Zuora

With the addition of these data industry veterans, Acceldata will accelerate development of its multidimensional data observability solutions for enterprise customers in cloud and hybrid environments.

Key Points: 
  • With the addition of these data industry veterans, Acceldata will accelerate development of its multidimensional data observability solutions for enterprise customers in cloud and hybrid environments.
  • "Gaj, Stuart, and Tristan are experts in the fields of data architecture and modern data platforms and will help us drive a multicloud data observability strategy that supports enterprise Chief Data Officers and data engineering teams."
  • Acceldata enables data engineers to optimize data environments, especially in the cloud, so data is reliable, highly consumable, and most importantly, used to support an organization's business objectives.
  • Having led partnerships for big data companies providing multidimensional, large-scale data infrastructure and at leading SaaS companies built on modern data architectures, I have seen first-hand the acute challenges of managing complex operational data.

Syniti Completes Q3 with Record Software and Alliance Partner Bookings, Strong Growth in Services, Enhanced Product Features and New Global 2000 Customers

Retrieved on: 
Monday, November 15, 2021
Knowledge, Cloud, Efficiency, Organization, Heart, Global Alliance for Genomics and Health, Data management, Customer relationship management, Growth, SVP, DMR, Named-entity recognition, Trust, Food, Cloud (operating system), Risk, Construction, Management, Online shopping

Joint delivery and execution with partners also continues to be a strong growth and demand area for Syniti consulting and delivery services.

Key Points: 
  • Joint delivery and execution with partners also continues to be a strong growth and demand area for Syniti consulting and delivery services.
  • After launching in 2019 and reinforcing its commitment to Global Alliances last year, Syniti's business with Alliance Partners grew triple digits.
  • More than 30% of Syniti's total software bookings in the third quarter were also initiated from the Alliance Partner Ecosystem.
  • "More global enterprises are turning to Syniti to deliver critical business advantages with their data," said Kevin Campbell, Syniti CEO.

$8.4 Bn CRISPR Markets - Global Forecasts from 2021 to 2026: Escalating R&D to Provide Opportunities Market Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, Genetics, Health, CRISPR, CRISPR Therapeutics, Biotechnology, Shorthand, Therapy, Gene editing, Deletion, National Center for Biotechnology Information, Anti-transglutaminase antibodies, Collection, Genome, CAGR, DNA, Amyotrophic lateral sclerosis, Cancer, Patient, Global Alliance for Genomics and Health, Lists of diseases, Library, GA4GH, Agriculture, USDA, Risk, Plasmid, Genomics, Brassica, Technology, PerkinElmer, Global Alliance, Genetic engineering, ALS, Qiagen, Friedreich's ataxia, Research, Haemophilia, Birth, Investment, Industry, Pharmaceutical industry, Vaccine

The global CRISPR market is a growing with major investments from developed countries.

Key Points: 
  • The global CRISPR market is a growing with major investments from developed countries.
  • The growing need for drug research, the risk of congenital abnormalities, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward.
  • The escalating geriatric population, Changes in lifestyles, and investment in cutting-edge research technologies are also augmenting the market size.
  • A lot of research and development happening in the market is anticipated to boost the opportunities through the inclining market trends.

Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer

Retrieved on: 
Wednesday, August 11, 2021
Biotechnology, Genetics, Health, People, Bristol, Global Alliance for Genomics and Health, B-cell lymphoma, Rutgers University, Therapy, Business development, Hepatitis C, Patient, MBA, Bluebird bio, Hoffmann-La Roche, Cystic fibrosis, National, BCMA, Hereditary angioedema, National Cancer Institute, Congenital disorders of amino acid metabolism, Atlas, RA, Pharming, Program, Heart, Sutro Biopharma, Cornell University, Senior, Rochester, Alta Partners, Celgene, Character, Environment, Doctor of Philosophy, Bristol Myers Squibb, BS, CD19, University, Investment, BMS, Atlas Venture, Oslo-Fergene, Graduate school, Culture, Growth, Krishnan, Management, Pharmaceutical industry

I am thrilled to welcome both Krishnan and Brad to Be Bio.

Key Points: 
  • I am thrilled to welcome both Krishnan and Brad to Be Bio.
  • Krishnan brings an exceptional track record building, rapidly scaling, and effectively leading operations that have delivered multiple highly impactful cell therapy products to patients, said Joanne Smith-Farrell, PhD, Chief Executive Officer at Be Bio.
  • Prior to joining Be Bio, Krishnan served as Senior Vice President, Global Cell Therapy Franchise Lead at Bristol Myers-Squibb (BMS).
  • He currently serves as a non-executive director on the board of JW Therapeutics, a leading cell therapy company in China.

DNAstack Launches COVID-19 Beacon to Accelerate Sharing Genomic Data in the Fight Against Novel Coronavirus

Retrieved on: 
Friday, March 20, 2020
Genomics, Global Alliance for Genomics and Health, Computer virus

"What we know about the virus is changing hourly as researchers and clinicians accumulate and analyze data.

Key Points: 
  • "What we know about the virus is changing hourly as researchers and clinicians accumulate and analyze data.
  • At DNAstack, we are looking to deploy our technologies for biomedical data access, discovery, and analysis to support researchers investigating the virus, starting with Beacon.
  • The COVID-19 Beacon is compliant with the Beacon API, an internationally recognized open-source protocol developed by the Global Alliance for Genomic and Health (GA4GH).
  • DNAstack develops standards and technologies for scientists to more efficiently find, access, and analyze the world's exponentially growing volumes of genomic and biomedical data.